98%
921
2 minutes
20
The past several decades have seen a paradigm shift with the integration of evolutionary thinking into studying cancer. The evolutionary lens is most commonly employed in understanding cancer emergence, tumour growth and metastasis, but there is an increasing realization that cancer defences both between tissues within the individual and between species have been influenced by natural selection. This special issue focuses on discoveries of these deeper evolutionary phenomena in the emerging area of 'comparative oncology'. Comparing cancer dynamics in different tissues or species can lead to insights into how biology and ecology have led to differences in carcinogenesis, and the diversity, incidence and lethality of cancers. In this introduction to the special issue, we review the history of the field and outline how the contributions use empirical, comparative and theoretical approaches to address the processes and patterns associated with 'Peto's paradox', the lack of a statistical relationship of cancer incidence with body size and longevity. This burgeoning area of research can help us understand that cancer is not only a disease but is also a driving force in biological systems and species life histories. Comparative oncology will be key to understanding globally important health issues, including cancer epidemiology, prevention and improved therapies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581022 | PMC |
http://dx.doi.org/10.1098/rstb.2014.0177 | DOI Listing |
Transplantation
September 2025
General Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Background: Mortality after liver transplantation (LT) for hepatocellular carcinoma (HCC) is mainly driven by HCC recurrence. We sought to determine whether post-recurrence survival (PRS) has improved during the last 2 decades.
Methods: Using the Scientific Registry of Transplant Recipients, we included all patients who underwent LT for HCC between 2003 and 2020 and experienced HCC recurrence.
Ann Surg Oncol
September 2025
Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.
Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.
Brachytherapy
September 2025
Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, 10-6 Sakaemachi, Fukushima, Fukushima, 960-8516, Japan.
Purpose: This study presents the dose-based intra-preplan (DIP) method for intracavitary/interstitial brachytherapy (IC/ISBT) in cervical cancer, optimizing catheter configurations based on dose distribution. This study aimed to assess the DIP method's clinical feasibility and efficacy.
Methods And Materials: The DIP method incorporates the implant modeling function and the hybrid inverse planning optimization algorithm in Oncentra Brachy.
Best Pract Res Clin Haematol
September 2025
Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Electronic address:
Precursor plasma cell disorders include monoclonal gammopathy of undermined significance (MGUS) and smoldering multiple myeloma (SMM). These conditions carry a variable risk of progression to symptomatic myeloma and there are ongoing efforts to improve risk stratification to identify patients that are at highest risk of progression. Advanced imaging plays a crucial role in diagnosis and monitoring, and more sensitive tools to measure serum monoclonal proteins and circulating tumor cells are being developed.
View Article and Find Full Text PDFClin Pharmacol Ther
September 2025
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
This cross-sectional study aims to demonstrate the impact of China's 2015 review and approval reform on the delays in market entry for novel geriatric drugs, as well as the capability of domestic innovation in developing geriatric drugs. We analyzed the novel geriatric drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2024 to assess the drug lags in China by using the EU and Japan as comparators. During this period, the FDA approved a total of 183 novel drugs targeting geriatric diseases, of which 109 were also approved by the NMPA.
View Article and Find Full Text PDF